Zur Rose Group AG’s (VTX:ROSE): Zur Rose Group AG operates an e-commerce pharmacy and a wholesale business for medical and pharmaceutical products under the Zur Rose and DocMorris brands in Germany, Switzerland, and rest of Europe. On 31 December 2019, the CHF1.9b market-cap posted a loss of -CHF52.4m for its most recent financial year. As path to profitability is the topic on ROSE’s investors mind, I’ve decided to gauge market sentiment. I’ve put together a brief outline of industry analyst expectations for ROSE, its year of breakeven and its implied growth rate.
Consensus from the 8 Consumer Retailing analysts is ROSE is on the verge of breakeven. They anticipate the company to incur a final loss in 2021, before generating positive profits of CHF28m in 2022. Therefore, ROSE is expected to breakeven roughly 2 years from today. In order to meet this breakeven date, I calculated the rate at which ROSE must grow year-on-year. It turns out an average annual growth rate of 60% is expected, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.
Given this is a high-level overview, I won’t go into details of ROSE’s upcoming projects, however, take into account that by and large a high forecast growth rate is not unusual for a company that is currently undergoing an investment period.
Before I wrap up, there’s one issue worth mentioning. ROSE currently has a relatively high level of debt. Generally, the rule of thumb is debt shouldn’t exceed 40% of your equity, which in ROSE’s case is 79%. Note that a higher debt obligation increases the risk in investing in the loss-making company.
There are key fundamentals of ROSE which are not covered in this article, but I must stress again that this is merely a basic overview. For a more comprehensive look at ROSE, take a look at ROSE’s company page on Simply Wall St. I’ve also put together a list of pertinent aspects you should further examine:
- Historical Track Record: What has ROSE’s performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Zur Rose Group’s board and the CEO’s back ground.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Love or hate this article? Concerned about the content? Get in touch with us directly. Alternatively, email firstname.lastname@example.org.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Thank you for reading.